Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease
Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Usin...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/412178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552831842779136 |
|---|---|
| author | Thomas Lindebo Holm Steen Seier Poulsen Helle Markholst Stine Reedtz-Runge |
| author_facet | Thomas Lindebo Holm Steen Seier Poulsen Helle Markholst Stine Reedtz-Runge |
| author_sort | Thomas Lindebo Holm |
| collection | DOAJ |
| description | Animal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease. |
| format | Article |
| id | doaj-art-254aa239ba074798aad8cd8d00ffcc28 |
| institution | Kabale University |
| issn | 2090-8040 2042-0099 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Inflammation |
| spelling | doaj-art-254aa239ba074798aad8cd8d00ffcc282025-02-03T05:57:40ZengWileyInternational Journal of Inflammation2090-80402042-00992012-01-01201210.1155/2012/412178412178Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's DiseaseThomas Lindebo Holm0Steen Seier Poulsen1Helle Markholst2Stine Reedtz-Runge3Department of Immunopharmacology, Novo Nordisk A/S, 2760 Måløv, DenmarkDepartment of Medical Anatomy, The Panum Institute, University of Copenhagen, 2200 Copenhagen, DenmarkDepartment of Immunopharmacology, Novo Nordisk A/S, 2760 Måløv, DenmarkDepartment of Immunopharmacology, Novo Nordisk A/S, 2760 Måløv, DenmarkAnimal models are important tools in the development of new drug candidates against the inflammatory bowel diseases (IBDs) Crohn's disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the effect of currently used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin, enrofloxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-Ig, and anti-IL-6 effectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies, antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the adoptive transfer model and the inflammatory bowel diseases have some main inflammatory pathways in common. The finding that some well-established IBD therapeutics do not have any effect in the model highlights important differences between the experimental model and the human disease.http://dx.doi.org/10.1155/2012/412178 |
| spellingShingle | Thomas Lindebo Holm Steen Seier Poulsen Helle Markholst Stine Reedtz-Runge Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease International Journal of Inflammation |
| title | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease |
| title_full | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease |
| title_fullStr | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease |
| title_full_unstemmed | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease |
| title_short | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease |
| title_sort | pharmacological evaluation of the scid t cell transfer model of colitis as a model of crohn s disease |
| url | http://dx.doi.org/10.1155/2012/412178 |
| work_keys_str_mv | AT thomaslindeboholm pharmacologicalevaluationofthescidtcelltransfermodelofcolitisasamodelofcrohnsdisease AT steenseierpoulsen pharmacologicalevaluationofthescidtcelltransfermodelofcolitisasamodelofcrohnsdisease AT hellemarkholst pharmacologicalevaluationofthescidtcelltransfermodelofcolitisasamodelofcrohnsdisease AT stinereedtzrunge pharmacologicalevaluationofthescidtcelltransfermodelofcolitisasamodelofcrohnsdisease |